BO
Therapeutic Areas
Nanobiotix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NBTXR3 | Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Phase III |
| NBTXR3 + anti-PD-1 | Solid Tumors | Phase I |
| Curadigm Platform Programs | Undisclosed | Discovery/Preclinical |
Leadership Team at Nanobiotix
LL
Laurent Levy, PhD
Chief Executive Officer
BV
Bart Van Rhijn
Chief Financial and Business Officer
AH
Anne-Juliette Hermant
Chief People Officer
LK
Louis Kayitalire, MD
Chief Medical Officer
AL
Anne-Sophie Larivière
Vice President, Strategy & Operational Excellence
GM
Gary M. Phillips, MD
Chairman of Supervisory Board
AH
Alain Herrera, MD
Supervisory Board Member
ES
Enno Spillner
Supervisory Board Member
AG
Anne-Marie Graffin
Supervisory Board Member
MA
Margaret A. Liu, MD
Supervisory Board Member